Merck MRK and AiCuris today announced that they have entered into an exclusive
worldwide licensing agreement for AiCuris' novel portfolio of
investigational medicines targeting Human Cytomegalovirus (HCMV),
including letermovir (AIC246), an oral, late-stage antiviral candidate
being investigated for the treatment and prevention of HCMV infection in
transplant recipients.
"There is a significant need for additional medicines for the treatment
of HCMV infection, which is one of the most common viral infections
affecting organ and bone marrow transplant patients," said Dr. Roger
Pomerantz, senior vice president, Worldwide Licensing and Knowledge
Management, and Infectious Disease Franchise Head, Merck Research
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in